Glycomics / Glycobiology Market : Technological Advancements in Glycomics Instrumentation

This study involved four major activities in estimating the current size of the glycomics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. 

According to the new market research report by MarketsandMarkets, global glycomics market is estimated to grow from USD 1.0 billion in 2020 to USD 2.0 billion by 2025, at a CAGR of 13.8%.

The growth of Glycomics Market is majorly driven by the increasing research activities on glycomics, rising R&D investments in pharmaceutical and biotechnology companies, growth in the proteomics market. On the other hand, emerging countries such as India and China providing lucrative opportunities for players operating in this segment.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525

Based on application, the glycomics market is segmented into drug discovery & development, disease diagnostics, and other applications. Drug discovery & development is the largest and the fastest-growing application segment in the market, majorly due to the increasing R&D investments in pharmaceutical and biotechnology companies and the growing number of drug discovery research activities in academic research institutes.

The market is categorized into five product segments, namely, enzymes, instruments, kits, carbohydrates, and reagents & chemicals. The enzymes segment is expected to dominate the market in 2020 and is projected to grow at the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the consumable nature of enzymes and their wide applications in a variety of R&D and drug discovery procedures.

The Geographical Landscape of the Market Include:

The global glycomics market is segmented into North America (US and Canada), Europe (Germany, the UK, France, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, Australia, and the Rest of Asia Pacific), and the Rest of the World (Latin America and the Middle East and Africa). In 2020, North America is expected to dominate the global market, followed by Europe. The largest share of North America is mainly attributed to increasing investments in glycomics research, rising R&D investments in pharmaceutical companies for drug discovery and the presence of all key players.

Request for sample pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525

Leading Key Players :

Merck KGaA (Germany), Agilent Technologies (US), Thermo Fisher Scientific (US), New England Biolabs (US), Shimadzu Corporation (Japan), Takara Bio (Japan), S-BIO (subsidiary of Sumitomo Bakelite Co. Ltd., Japan), Waters Corporation (US), Asparia Glycomics S.L. (Spain), Bio-Techne (US), Bruker Corporation (US), Danaher Corporation (US), RayBiotech (US), Z Biotech (US), Chemily Glycoscience (US), Dextra Laboratories (UK), Lectenz Bio (US), and Ludger Ltd. (UK).

Merck was the leading player in the market in 2018. Strong business operations across all key regions, coupled with a strong brand image, have made Merck a leading player in this market. Over the last few years, the company has been focusing on R&D activities and invested approximately 2.5–4.0% of its life science revenue on R&D activities. The company has a strong presence in North America and generated 35.1% of its total life science revenue from the North American market in 2018. Also, the company is making strategic investments in high-growth Asian markets to strengthen its Life Science business segment.

Recent Developments

• In June 2019, Agilent Technologies (US) has launched InfinityLab LC/MSD iQ System
• In June 2018, Thermo Fisher Scientific (US) had launched UHMR Hybrid Quadrupole-Orbitrap Mass Spectrometer.